Dennis Joseph Slamon (born August 6, 1948), is an American oncologist and chief of the division of Hematology-Oncology at UCLA. He is best known for his work identifying the HER2/neu oncogene that is amplified in 25–33% of breast cancer patients and the resulting treatment trastuzumab. Slamon’s attention early in his life.It was not, Dr. Slamon acknowledges, the most obvious choice. UCLA today is a top-tier academic institution, with a medical school that is ranked No. 6 in the nation for research. The impact that DrDennisSlamon‘s work has had on the field of cancer research is immense, and extends very substantially beyond that of his now famous and ground-breaking discoveries concerning the Her- 2 oncogene. DennisSlamon, MD, PhD, is director of clinical and translational research at the UCLA Health Jonsson Comprehensive Cancer Center and chief of hematology/oncology at the David Geffen School of Medicine at UCLA. Milo Mitchell/UCLA Jonsson Comprehensive Cancer Center. DennisSlamon, a pivotal figure in oncology and a professor at the David Geffen School of Medicine at UCLA, has received a distinguished acknowledgment: election to. Slamon, MD, PhD, is a prominent oncologist and researcher, serving as a Professor of Medicine, Chief of the Division of Hematology/Oncology, and Executive Vice Chair for Research in UCLA’s Department of Medicine.
